Company Announcements

Supply Agreement

Source: RNS
RNS Number : 2582R
Directa Plus PLC
05 July 2022
 

5 July 2022

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Supply Agreement

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to announce that it has signed a supply agreement with Officine di Cartigliano, for its patented G+® pristine graphene nanoplatelets technology, worth €150,000 over one year on a take or pay basis.

 

Officine di Cartigliano is the Italian based leader in the production of tanning equipment for the textile industry and will be using a formulation of the Company's G+® based textile finishing application to improve the performance of its equipment, particularly to address antistatic issues.

 

Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "We are very pleased to be working with Officine di Cartigliano. We have the know-how and the product to aid Cartigliano on this technical industrial application. Innovation is not just having good ideas but knowing how to transform those ideas into significant business opportunities for our partners."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO / Giorgio Bonfanti, CFO




Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald / Adam Rae




Singer Capital Markets (Joint Broker)

+44 20 7496 3069

Rick Thompson / Phil Davies




Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson / Heather Armstrong


 

About Directa Plus

Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.

 

This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic product, without unwanted by-products. Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+®) have multiple applications due to its properties. These G+® products can be categorised into various families, with different products being suitable for specific practical applications.

 

Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and has been listed on the AIM market of the London Stock Exchange since May 2016. The Company holds the Green Economy Mark from London Stock Exchange which recognises companies that contribute to the global green economy.

 

-ends-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKQBDPBKDCOK